Invesco Biotechnology & Genome ETF
PBE
101 hedge funds and large institutions have $77.1M invested in Invesco Biotechnology & Genome ETF in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 18 increasing their positions, 22 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
6% more capital invested
Capital invested by funds: $73M → $77.1M (+$4.08M)
4% more funds holding
Funds holding: 97 → 101 (+4)
2.89% more ownership
Funds ownership: 24.94% → 27.83% (+2.9%)
18% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWA
Artemis Wealth Advisors
New York
|
+$3.95M |
| 2 |
Morgan Stanley
New York
|
+$2.23M |
| 3 |
CAN
Cetera Advisor Networks
El Segundo,
California
|
+$1.56M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$786K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$707K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stifel Financial
St. Louis,
Missouri
|
-$684K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$654K |
| 3 |
PA
PFG Advisors
Phoenix,
Arizona
|
-$639K |
| 4 |
Goldman Sachs
New York
|
-$511K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$231K |
PBE Hedge Fund Activity: Q4 2021 in Review
101 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Invesco Biotechnology & Genome ETF (PBE) for Q4 2021, worth a combined $77.1M — up 5.6% from $73M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PBE positions and 8 closed out — a net gain of 6 holders — while 18 added to existing stakes and 22 trimmed.
The largest buyer was Artemis Wealth Advisors, adding an estimated $3.95M. The largest seller was Stifel Financial, cutting an estimated $684K.
- 101 institutional investors held Invesco Biotechnology & Genome ETF (PBE) as of Q4 2021, up from 97 in Q3 2021.
- Funds reported $77.1M of Invesco Biotechnology & Genome ETF stock for Q4 2021, up 5.6% quarter-over-quarter.
- 14 funds opened new Invesco Biotechnology & Genome ETF positions in Q4 2021 and 8 closed out, a net change of +6 holders.
- The largest Invesco Biotechnology & Genome ETF buyer in Q4 2021 was Artemis Wealth Advisors, an estimated $3.95M added.
- The largest Invesco Biotechnology & Genome ETF seller in Q4 2021 was Stifel Financial, an estimated $684K sold.
Based on aggregated 13F filings for Q4 2021.